LncRNAs in cardiac hypertrophy: From basic science to clinical application

Area of Science:

• Cardiology
• Molecular Biology
• Genetics

Background:

• Cardiac hypertrophy is a pathological remodeling of cardiomyocytes, a hallmark of cardiomyopathy.
• Both genetic mutations and external factors like pressure overload can trigger cardiac hypertrophy.
• Long non-coding RNAs (lncRNAs) are increasingly recognized for their role in regulating cardiac hypertrophy.

Purpose of the Study:

• To review recent research on the role of lncRNAs in cardiac hypertrophy.
• To analyze lncRNAs as potential therapeutic targets for cardiac hypertrophy.
• To discuss the implications of lncRNA research for future gene therapy approaches.

Main Methods:

• Literature review of recent studies on lncRNAs and cardiac hypertrophy.
• Analysis of molecular mechanisms linking lncRNA dysregulation to cardiac hypertrophy.
• Evaluation of therapeutic potential of lncRNAs in preclinical and clinical contexts.

Main Results:

• Abnormal lncRNA expression is linked to impaired sarcomere function, calcium handling, and mitochondrial metabolism in cardiac hypertrophy.
• Several lncRNAs have demonstrated therapeutic potential in preventing or reversing cardiac hypertrophy.
• Advancements in oligonucleotide delivery systems pave the way for lncRNA-based gene therapies.

Conclusions:

• lncRNAs represent promising therapeutic targets for managing cardiac hypertrophy.
• Gene therapy targeting lncRNAs offers a potential strategy to improve patient prognosis for cardiomyopathy.
• Further research into lncRNA mechanisms and delivery systems is crucial for clinical translation.